ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2221

Major Adverse Cardiovascular Events Are More Common in Rheumatoid Arthritis Than in Psoriatic Arthritis and Are Associated with Different Risk Factors

Allen P. Anandarajah1, Katherine C. Saunders2, George W. Reed3, Alina U. Onofrei3, Jeffrey D. Greenberg4 and Christopher T. Ritchlin5, 1Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, 2Corrona, LLC., Southborough, MA, 3University of Massachusetts Medical School, Worcester, MA, 4NYU Hospital for Joint Diseases, New York, NY, 5Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Cerebrovascular disease, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid Arthritis (RA) is associated with increased cardiovascular mortality and morbidity rates. Similarly several studies have reported an increased risk for cardiovascular events in patients with psoriasis. There, however, are few studies that have reported on the risk factors for major adverse cardiovascular events (MACE) in patients with psoriatic arthritis (PsA). Furthermore, no studies have compared the risk for MACE in PsA patients with RA patients.

Objective:To determine if the prevalence and risk factors for MACE in PsA patients and compare with prevalence and risk factors for MACE in RA patients.

Methods: All patients with RA and PsA with at least one follow up visit were identified from the Consortium of Rheumatology Researchers of North America (CORRONA) database. The incident rates (IR) for MACE per 100 person years of follow up were estimated. MACE was defined as myocardial infarction, stroke/ transient ischemic attacks and death secondary to cardiovascular events.  Follow up time was counted from enrollment in CORRONA to the first reported event or the last follow up. Cox regression models estimated the association of the following covariates with MACE rates: age, gender, body mass index (BMI), physician global assessment of disease activity (PGDA), disease duration, bone erosion status, disease modifying anti-rheumatic drugs, steroids, aspirin, smoking, diabetes, and hypertension.

Results: A total of 25,700 RA patients (81,104 person years of follow-up) and 3,909 PsA patients (11,828 person years of follow-up) were identified. Patients with RA were older, had a lower BMI, higher MD global assessment scores, longer disease duration, were less likely to have diabetes and less likely to be on biologic therapies but more likely to be on DMARDs or steroids than PsA patients. The percentage of previous and current smokers was similar between RA and PsA patients. The unadjusted IR for MACE events in RA and PsA patients were 0.65 (95% CI: 0.60-0.71) and 0.35 (CI: 0.25-0.47) respectively. The unadjusted IR for MACE events was higher in RA patients with erosions (0.71, 0.61-0.81) compared with those without erosions (0.53, 0.45-0.63) but in PsA patients the IR was slightly higher in those without erosions (0.33, 0.19-0.55) than in those with erosions (0.25, 0.10-0.51). Age, gender, history of hypertension, disease duration, steroids, diabetes and PGDA were identified as significant risk factors for MACE in the RA population. In contrast, in PsA patients, age, hypertension, gender and PGDA were the only risk factors.

Conclusion: Unadjusted MACE events are more common in RA than in PsA. Only age, gender, hypertension, and PGDA were common risk factors to both forms of arthritides, although events and follow up time in PsA patients limited the number of multiple covariates that could be examined.

Table 1: Hazard Ratios (HR) from Multivariate Cox Regression Models in RA and PsA patients

 

HR for risk of MACE events

 

RA patients

PsA patients

Female

0.55  [0.46, 0.67]

0.41  [0.21, 0.80]

Age

   <50

  50-60

  60-70

  ≥70

1

2.16  [1.46, 3.19]

3.52  [2.41, 5.15]

7.07  [4.85, 10.30]

1

3.32  [1.05, 10.51]

8.61  [2.76, 26.91]

8.75  [2.46, 31.05]

Smoking status

    Never

    Previous

    Current

1

1.19  [0.95, 1.48]

2.28  [1.81, 2.86]

1

1.74  [0.85, 3.56]

2.55  [1.06, 6.11]

History of Hypertension

1.39  [1.16, 1.67]

2.08  [1.07, 4.03]

MD global assessment

(risk per unit change)

1.006  [1.002, 1.010]

1.018  [1.003, 1.033]

History of diabetes

1.59  [1.22, 2.07]

1.08  [0.46, 2.51]

Duration of disease

(risk per yr)

1.016  [1.008, 1.024]

 

Steroid use

1.55  [1.30, 1.86]

 


Disclosure:

A. P. Anandarajah,
None;

K. C. Saunders,

;

G. W. Reed,
None;

A. U. Onofrei,
None;

J. D. Greenberg,

Corrona,

4,

AstraZeneca, Novartis, Pfizer, CORRONA,

5;

C. T. Ritchlin,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/major-adverse-cardiovascular-events-are-more-common-in-rheumatoid-arthritis-than-in-psoriatic-arthritis-and-are-associated-with-different-risk-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology